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Knowing COVID-19 epidemiological distributions, such as the time from patient admission to
death, is directly relevant to effective primary and secondary care planning, and moreover, the
mathematical modelling of the pandemic generally.1 Here we determine epidemiological distributions
for patients hospitalised with COVID-19 using a large dataset (range N = 21,000 − 157,000) from
the Brazilian SIVEP-Gripe (Sistema de Informao de Vigilncia Epidemiolgica da Gripe) database.2
We fit a set of probability distribution functions and estimate a symptom-onset-to-death mean of
15.2 days for Brazil, which is lower than earlier estimates of 17.8 days based on early Chinese data.3
A joint Bayesian subnational model is used to simultaneously describe the 26 states and one federal
district of Brazil, and shows significant variation in the mean of the symptom-onset-to-death time,
with ranges between 11.2− 17.8 days across the different states. We find strong evidence in favour
of specific probability distribution function choices: for example, the gamma distribution gives the
best fit for onset-to-death and the generalised log-normal for onset-to-hospital-discharge. Our results
show that epidemiological distributions have considerable geographical variation, and provide the
first estimates of these distributions in a low and middle-income setting. At the subnational level,
variation in COVID-19 outcome timings are found to be correlated with poverty, deprivation and
segregation levels, and weaker correlation is observed for mean age, wealth and urbanicity.
Keywords: COVID-19, symptom-onset-to-death, onset-to-admission, onset-to-diagnosis, onset-to-ICU,
admission-to-death, income, Brazil, HMC, model selection
I. INTRODUCTION
Surveillance of COVID-19 has progressed from ini-
tial reports on 31st-Dec-2019 of pneumonia with un-
known etiology in Wuhan, China,4 to the confirmation
of 9, 826 cases of SARS-CoV-2 across 20 countries one
month later,5 to the current pandemic of greater than
12 million confirmed cases and 500, 000 deaths globally
to date.6 Early estimates of epidemiological distributions
provided critical input that enabled modelling to identify
the severity and infectiousness of the disease. The onset-
to-death distribution,7,8 characterising the range of times
observed between the onset of first symptoms in a patient
and their death, has for example proved crucial in early
estimates of the Infection Fatality Ratio (IFR),3 and was
similarly integral to recent approaches to modelling the
transmission dynamics of SARS-CoV-2.1,9–13
Initial estimates of COVID-19 epidemiological dis-
tributions necessarily relied on few data points, with
the events comprising these distributions occurring a
period of time that was short compared to the tem-
poral pathologies of the disease progression, resulting
in large credible intervals and a sensitivity to time-
series censoring effects.3 Global surveillance of the dis-
ease over the past 197 days has provided more data
to re-evaluate the time-delay distributions of the dis-
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ease. In particular, public availability of a large num-
ber of patient-level hospital records – currently over
390, 000 in total – from the SIVEP-Gripe (Sistema de
Informao de Vigilncia Epidemiolgica da Gripe) database
published by Brazil’s Ministry of Health (MoH),2 pro-
vides an opportunity to make robust statistical estimates
of the onset-to-death and other time-delay distributions
such as onset-to-diagnosis, length of ICU stay, onset-to-
hospital-admission, onset-to-hospital-discharge, onset-
to-ICU-admission, and hospital-admission-to-death.
In this work we fit and present an analysis of these epi-
demiological distributions, with the paper set out as fol-
lows. Section II describes the data used from the SIVEP-
Gripe database,2 and the methodological approach ap-
plied to fit distributions using a hierarchical Bayesian
model. Section III provides a description of the results
from this study from fitting epidemiological distributions
at national and subnational level to a range of proba-
bility distribution functions. The results are discussed
in Section IV, including associations with socioeconomic
factors, such as education, segregation, and poverty, and
conclusions are given in Section V.
II. METHODS
A. Data
The SIVEP-Gripe database provides detailed patient-
level records for all individuals hospitalised with severe
acute respiratory syndrome, including all suspected or
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2confirmed cases of severe COVID-19.2 The records in-
clude the date of admission, date of onset of symptoms,
state where the patient lives, state where they are being
treated, and date of outcome (death or discharge), among
other diagnosis related variables. We extracted the data
for confirmed COVID-19 records starting on 25th Febru-
ary and considered records in our analysis ending on 7th
July. The dataset was filtered to obtain rows for length
of ICU stay, onset-to-death, onset-to-diagnosis, onset-to-
admission, onset-to-ICU, admission-to-death and onset-
to-hospital-discharge distributions. Onset-to-diagnosis
was split into the diagnosis confirmed by PCR and
those confirmed by other methods, such as rapid an-
tibody and antigen tests, called non-PCR throughout
this manuscript. Entries resulting in distribution times
greater than 133 days were considered a typing error and
removed, as the first recorded COVID-19 case in Brazil
was on 25th February.14
Additional filtering to the data was applied for
onset-to-ICU-admission, onset-to-hospital-admission and
onset-to-death in order to eliminate bias introduced by
potentially erroneous entries identified in the data for
these distributions. We removed the rows where admis-
sion to the hospital or ICU or death happened on the
same day as onset of symptoms, assuming that these
were actually incorrectly inputted entries. The decision
to test removing the first day is motivated firstly by the
observation of a number of conspicuous data entry er-
rors in the database, and secondly by anomalous spikes
corresponding to same-day events observed in these dis-
tributions. An example of the anomalous spikes in the
onset-to-death distribution is shown in Appendix Figure
4 for selected states.
Sensitivity analyses on data inclusion, regarding the
removal of anomalous spikes in first-day data indicative
of reporting errors (e.g. in onset to hospital admission),
and regarding the sensitivity of the dataset to time-series
censoring effects, are set out in the Results section III C.
A summary of the data, including number and a range
of samples per variable from the SIVEP-Gripe dataset
is given in Table I. A breakdown of the number of data
samples per state is provided in Appendix Table IX.
Basic exploratory analysis to explain geographic varia-
tion observed in time-delay distributions adopts GeoSES
(ndice Socioeconmico do Contexto Geogrfico para Estu-
dos em Sade),15 which measures Brazilian socioeconomic
characteristics through an index composed of education,
mobility, poverty, wealth, deprivation, and segregation.
We investigate correlations between the GeoSES indica-
tors and the time-delay means that we estimate at the
state level. Additionally, we consider correlations with
the mean age of the population of the state and the
percentage of people living in urban areas, data we ob-
tained from Instituto Brasileiro de Geografia e Estatstica
(IBGE ).16
Table I. Summary of the distribution data extracted from
SIVEP-Gripe database.2 Number of samples (Nsamples) is
given for the whole country.
Distribution Nsamples Range (days)
Onset-to-death 59,271 1-114
Onset-to-diagnosis (non-PCR) 19,438 0-102
Onset-to-diagnosis (PCR) 156,558 0-129
Onset-hospital admission 141,618 1-129
Onset-hospital discharge 69,478 0-120
Onset-ICU admission 46,617 0-101
ICU stay 21,709 0-89
Hospital admission-death 52,821 0-99
B. Model fitting
Gamma, Weibull, log-normal, generalised log-
normal,17 and generalised gamma18 probability
distribution functions (PDFs) are fitted to several
epidemiological distributions, with the specific param-
eterisations provided in the Appendix Section IX A.
The parameters of each distribution are fitted in a joint
Bayesian hierarchical model, using data from the 26
states and one federal district of Brazil, extracted and
filtered to identify specific epidemiological distributions
such onset-to-death, ICU-stay, and so on.
As an example consider fitting a gamma PDF for the
onset-to-death distribution. The gamma distribution for
the ith state is given by
Gamma(αi, βi) , (1)
where shape and scale parameters are assumed to be
positively constrained, normally distributed random vari-
ables
αi ∼ N(αBrazil, σ1) (2)
and
βi ∼ N(βBrazil, σ2) . (3)
The national level parameters αBrazil and βBrazil denote
the national level estimates, and
σ1 ∼ N+(0, 1) , σ2 ∼ N+(0, 1) , (4)
where N+(·) is a truncated normal. In this case, param-
eters αBrazil and βBrazil are estimated by fitting a gamma
distribution to the fully pooled data, that is including the
observation for all states. Prior probabilities for the na-
tional level parameters for each of the considered PDFs
are chosen to be N+(0, 1), except for the generalised
gamma distribution where we used: µBrazil ∼ N+(2, 0.5),
σBrazil ∼ N+(0.5, 0.5) and sBrazil ∼ N+(1.5, 0.5).
Posterior samples of the parameters in the model are
generated using Hamiltonian Monte Carlo (HMC) with
Stan.19,20 For each fit we use 4 chains and 2, 000 itera-
tions, with half of the iterations dedicated to warm-up.
3The preference for one fitted model over another is
characterised in terms of the Bayesian support, with the
model evidence calculated to see how well a given model
fits the data, and comparison between two models using
Bayes Factors. The details of how to estimate the model
evidence and calculate the Bayes Factors for each pair of
models are given in the Appendix Section IX A.
III. RESULTS
A. Brazil epidemiological distributions
Five trial probability distribution functions (PDFs) –
Weibull, gamma, log-normal, generalised log-normal and
generalised gamma – were fitted to the epidemiological
data shown in Figure 1.
All of the models’ fits were tested by using the
Bayes Factors based on the Laplace approximation and
corrected using thermodynamic integration,21–23 as de-
scribed in the Appendix IX A. The thermodynamic inte-
gration contribution was negligible suggesting the poste-
rior distributions are satisfactorily approximated as mul-
tivariate normal. The conclusions on the preferred PDF
were not sensitive to the choice of priors, that is the pre-
ferred model was still the favoured one even when more
informative priors were applied for all PDFs. The Bayes
Factors used for model selection are shown in the Ap-
pendix, Table V.
The gamma distribution provided the best fit to
the onset-to-death, ICU-stay and hospital-admission-
to-death data. For the remaining distributions –
onset-to-diagnosis (non-PCR), onset-to-diagnosis (PCR),
onset-to-hospital-discharge, onset-to-hospital-admission
and onset-to-ICU-admission – the generalised log-normal
distribution was the preferred model. The list of pre-
ferred PDFs for each distribution, together with the es-
timated mean, variance and PDFs’ parameter values for
the national fit are given in Table II. The 95% credible in-
tervals (CI) for parameters of each of the preferred PDFs
was less than 0.1 wide, therefore in the Table II we show
only point estimates.
Additionally, in Figure 1, in each instance the cumula-
tive probability distribution is given for the best model
fit, revealing that out of patients for whom COVID-19
is terminal, almost 70% die within 20 days of symptom
onset. Out of patients who die in the hospital, almost
60% die within the first 10 days since admission.
The estimated mean number of days for each distribu-
tion for Brazil is compared in Table III with values found
in the literature for China, US and France. The major-
ity of the data obtained through searching the literature
pertained to the early stages of the epidemic in China,
and no data was found for low- and middle-income coun-
tries. The mean onset-to-death time of 15.2 (95% CI
15.1 − 15.3) days, from a best-fitting gamma PDF, is
lower than the 17.8 (95% CI 16.919.2) days estimate,3
and 20.2 (95% CI 15.1 − 29.5) days estimate (14.5 days
without truncation) from Linton et al.13 In both cases,
estimates were based on a small sample size from the
beginning of the epidemic in China. The mean number
of days for hospital-admission-to-death for Brazil of 10.8
(95% CI 10.7 − 10.9) matches closely the 10 days esti-
mated by Salje et al.24
B. Subnational Brazilian epidemiological
distributions
The onset-to-death distribution, and other time-delay
distributions such as onset-to-diagnosis, length of ICU
stay, onset-to-hospital-admission, onset-to-hospital-
discharge, onset-to-ICU-admission, and hospital-
admission-to-death, have been fitted in a joint model
across the 26 states and one federal district of Brazil.
The mean number of days, plotted in Figure 2, shows
substantial subnational variability – e.g. the mean
onset-to-hospital-admission for Amazonas state was
estimated to be 9.9 days (95% CI 9.7-10.1), whereas in
Mato Grosso do Sul 6.7 (95% CI 6.4-7.1) days and Rio
de Janeiro - 7.2 days (95% CI 7.1-7.3). Amazonas state
had the longest average time from onset to hospital and
ICU admission. The state with the shortest average
onset to death time was Acre. Santa Catarina state on
the other hand had a longest average onset-to-death
and hospital-admission-to-death time, as well as longest
average ICU stay. For a visualisation of the uncertainty
in our mean estimates for each state, see the posterior
density plots in Appendix Figures 5 and 6. Additional
national and state-level results for the onset-to-death
gamma PDF, including the posterior plots for mean and
variance, are shown in Figure 7 in the Appendix.
We also observe discrepancies between the five geo-
graphical regions of Brazil, for example states belonging
to the southern part of the country (Paran, Rio Grande
do Sul and Santa Catarina) had a higher average ICU
stay and hospital admission to death time as compared
to the states in the North region. Full results, including
detailed estimates of mean, variance, and estimates for
each of the distribution’s parameters for Brazil and
Brazilian states can be accessed at https://github.
com/mrc-ide/Brazil_COVID19_distributions/blob/
master/results/results_full_table.csv.
C. Sensitivity analyses
In order to remove the potential bias towards shorter
outcomes from left- and right-censoring, we tested the
scenario in which the data to fit the models was trun-
cated. For example, based on a 95% quartile of 35 days
for the hospital-admission-to-death distribution, entries
with the starting date (hospital admission) after 2nd
June 2020 and those with an end-date (death) before 1st
April were truncated, and the models were refitted. With
censored parts of the data removed, the mean time from
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Figure 1. Histograms for ICU-stay, onset-to-diagnosis (PCR), onset-to-diagnosis (non-PCR), onset-to-ICU-admission, onset-
to-hospital-admission, onset-to-hospital-discharge and hospital-admission-to-death distributions show data for Brazil extracted
from the SIVEP-Gripe database.2 For each distribution solid lines are for fitted PDFs and the dashed line shows the cumulative
distribution function of the best-fitting PDF. The left hand side y-axis gives the probability for the PDFs and the right hand
side y-axis shows the cumulative probability. All values on the x-axes are given in days. State-level fits are shown in Figure 2
and Appendix Figures 5 and 6.
start to outcome increased for every distribution, e.g. for
hospital-admission-to-death it increased from 10.0 (95%
CI 9.9-10.0) to 10.8 (95 % CI 10.7-10.9), and for onset-
to-death it changed from 15.2 days (95% CI 15.1-15.3) to
16.0 days (95% CI 15.9-16.1). The effect truncation on
censored data is given in Appendix Figure 8.
To test the impact of keeping or removing entries iden-
tified as potentially resulting from erroneous data tran-
scription (see the Methods Section II), we fitted the PDFs
to some of the distributions on a national level with
and without those rows. For onset-to-hospital-admission,
onset-to-ICU and onset-to-death we find that generalised
gamma PDF was preferred when the first day of the dis-
tribution was included, and gamma (for onset-to-death)
and generalised log-normal PDFs if the first day was re-
moved. For hospital-admission-to-death, a gamma dis-
tribution fitted most accurately when the first day was
included, and Weibull when it was excluded. The ef-
fect of removing the first day results in means shifting
to the right by approximately 1 day for both onset-to-
hospital and ICU admission, and by 0.5 days for hospital-
admission-to-death (see Appendix Figure 8).
Sensitivity analysis regarding the model selection ap-
proach is detailed in Appendix IX A.
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Figure 2. Estimates of the mean time in days for ICU-stay, onset-to-death and each of the other probability distribution
functions (PDF) fitted in the joint model of Brazil. Estimates are grouped by the five regions of Brazil, North (blue), Northeast
(light-blue), Central-West (green), Southeast (orange), South (red), and are shown for Acre (AC), Amazonas (AM), Amap
(AP), Par (PA), Rondnia (RO), Roraima (RR), Tocantins (TO), Alagoas (AL), Bahia (BA), Cear (CE), Maranho (MA),
Paraba (PB), Piau (PI), Pernambuco (PE), Sergipe (SE), Rio Grande do Norte (RN), Distrito Federal (DF), Gois (GO), Mato
Grosso do Sul (MS), Mato Grosso (MT), Esprito Santo (ES), Minas Gerais (MG), Rio de Janeiro (RJ), So Paulo (SP), Paran
(PR), Rio Grande do Sul (RS), Santa Catarina (SC). For state Acre the onset-to-diagnosis (non-PCR) the mean diverged due
to the small number of samples (n=1). The full PDF for each mean estimate is given in Appendix Figures 5 and 6.
6Table II. For each COVID-19 distribution the preferred probability distribution function (PDF) with the largest Bayesian
support is listed, along with the estimated mean, variance and other parameter of the PDF. 95% credible intervals are given
in brackets for mean and variance. The parameters p1, p2 and p3 for the preferred PDFs gamma and generalised log-normal
(GLN) are given in the form Gamma(x|p1, p2) = Gamma(α, β) and GLN(x|p1, p2, p3) = GLN(µ, σ, s), with the formulae of
the PDFs given in the Appendix IX. The credible intervals for parameters p1, p2 and p3 are less than 0.1 wide, so only the
point estimates are shown. † The variance diverges for the onset-to-non-PCR-diagnosis PDF.
Distribution Preferred PDF Mean (days) Variance (days2) p1 p2 p3
Onset-to-death Gamma 15.2 (15.1, 15.3) 105.3 (103.7, 106.9) 2.2 0.1 -
Hospital-admission-to-death Gamma 10.0 (9.9, 10.0) 84.8 (83.2, 86.4) 1.2 0.1 -
ICU-stay Gamma 9.0 (8.9, 9.1) 64.9 (63.1, 66.8) 1.2 0.1 -
Onset-to-hospital-admission Gen. log-normal 7.8 (7.7, 7.8) 35.7 (35.0, 36.5) 1.8 0.6 1.8
Onset-to-hospital-discharge Gen. log-normal 17.6 (17.6, 17.7) 248.7 (233.7, 265.6) 2.7 0.3 1.2
Onset-to-ICU-admission Gen. log-normal 8.5 (8.4, 8.5) 48.0 (46.1, 50.0) 1.9 0.6 1.8
Onset-to-diagnosis (PCR) Gen. log-normal 12.5 (12.5, 12.6) 252.3 (236.4, 269.6) 2.3 0.3 1.2
Onset-to-diagnosis (non-PCR) Gen. log-normal 14.5 (14.3, 14.7) † 2.3 0.3 1.0
Table III. Epidemiological distributions for COVID-19 have been fitted for Brazil, and sources worldwide have been obtained
from the literature. Probability distribution function (PDF) means for Brazil have been obtained using MCMC, using the PDF
with the maximum Bayesian support for each data distribution (see Appendix Table V). All values are given in days, and 95%
CI are given in brackets unless stated otherwise. ∗ adjusted for censoring, † PCR confirmed, ‡ non-PCR confirmed, a median
(interquartile range), b mean (standard deviation).
Distribution Brazil China France US
Onset-to-death
15.2 (15.1, 15.3)
16.0∗ (15.9, 16.1)
17.8 (16.9, 19.2)3
18.8∗ (15.7, 49.7)3
14.5 (12.5, 17.0)13
20.2∗ (15.1, 29.5)13
13.59b (7.85)25
Hospital-admission-to-death
10.0 (9.9, 10.0)
10.8∗ (10.7, 10.9)
5.0a (3.0, 9.3)26
8.9 (7.3-10.4)13
13.0∗ (8.7-20.9)13
10.027
ICU-stay
9.0 (8.9, 9.1)
10.1∗ (9.9, 10.2) 8.0
a (4.0, 12.0)28 17.6 (17.0, 18.2)27
Onset-to-hospital-admission 7.8 (7.7, 7.8) 10.0a (7.0-12.0)26
Onset-to-hospital-discharge 17.6 (17.6, 17.7) 22.0a (18.0, 25.0)28
Onset-to-ICU-admission 8.5 (8.4, 8.5) 9.5a (7.0, 12.5)29
Onset-to-diagnosis
12.5†(12.5, 12.6)
14.5‡(14.3, 14.7) 5.5 (5.4, 5.7)
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IV. DISCUSSION
We have fitted multiple probability distribution func-
tions to a number of epidemiological datasets, such as
onset-to-death or onset-to-diagnosis, from the Brazil-
ian SIVEP Gripe database,2 using Bayesian hierarchi-
cal models. Our findings provide the first reliable es-
timates of the various epidemiological distributions for
the COVID-19 epidemic in Brazil and highlight a need
to consider a wider set of specific parametric distribu-
tions. Instead of relying on the ubiquitous gamma or
log-normal distributions, we show that often these PDFs
do not best capture the behaviour of the data – for in-
stance, the generalised log-normal is preferable for several
of the epidemiological distributions in Table II. These re-
sults can inform modelling of the epidemic in Brazil,30
and other low-middle-income countries,31 but we expect
they also have some relevance more generally.
In terms of modelling the epidemic in Brazil, the varia-
tion observed at subnational level – see Figure 2 – can be
shown to be important to accurately estimating disease
progression. Making use of the state-level custom-fitted
onset-to-death distributions reported here, we have esti-
mated the number of active infections on 23rd June 2020
across ten states spanning the five regions of Brazil, using
a Bayesian hierarchical renewal-type model.1,32,33 The
relative change in the number of active infections from
modelling the cases using heterogeneous state-specific
onset-to-death distributions, compared to using a single
common Brazil one is shown in Figure 3 to be quite sub-
stantial. The relative changes observed, up to 18% more
active infections, suggest assumptions of onset-to-death
homogeneity are unreliable and closer attention needs to
be paid when fitting COVID-19 models in large countries.
On the origin of the geographic variation displayed in
Figure 2 for the average distribution times across states,
there are multiple potential factors that could generate
the observed variability and in this work we present an
elementary exploratory analysis. We examine the cor-
relation between socioeconomic factors, such as educa-
7tion, poverty, income, etc., using a number of socioe-
conomic state-level indicators obtained from Barrozo et
al.(2020)15 and additional datasets containing the mean
age per state and percentage of people living in the urban
areas (urbanicity).16 The Pearson correlation coefficients,
shown in Table VII, suggest that segregation, poverty
and deprivation elements were most strongly correlated
with the analysed onset-time datasets. E.g. poverty was
strongly negatively correlated with hospital-admission-
to-death (-0.68), whereas income and segregation had
a high positive correlation coefficient for the same dis-
tribution (+0.60, +0.62 respectively). The strongest
correlation was observed for hospital-admission-to-death
and deprivation indicator, which measure access to san-
itation, electricity and other material and non-material
goods.15 Interestingly, the indicators measuring econom-
ical situation were more correlated with average hospi-
talisation times than mean age per state, which suggests
that although the low- and middle-income countries typ-
ically have younger populations, they are more likely to
observe incapability of the healthcare system to deal with
COVID-19 epidemic. More detailed analysis is necessary
to fully appreciate the impact of the economic compo-
nents on the COVID-19 epidemic response.
In the work presented we acknowledge numerous lim-
itations. The database from which distributions have
been extracted, though extensive, contains transcription
errors, and the degree to which these bias our estimates is
largely unknown. Secondly, the PDFs fitted are based on
observational hospital data, and therefore should be cau-
tiously interpreted for other settings. Thirdly, though we
have fitted PDFs at subnational as well as national level,
this partition is largely arbitrary and further work is re-
quired to understand the likely substantial effect of age,
sex, ethnic variation,34 co-morbidities, and other factors.
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Figure 3. This figure shows the percentage change in ac-
tive infections, estimated on the 23rd-Jun-2020, that results
from using state-specific onset-to-death distributions (see Ap-
pendix Table VI) compared to a single national-level one. The
effect for each state is coloured according to the mean of the
state’s onset-to-death gamma distribution. The mean onset-
to-death for Brazil is 15.2 days.
V. CONCLUSIONS
We provide the first estimates of common epidemiolog-
ical distributions for the COVID-19 epidemic in Brazil,
based on the SIVEP-Gripe hospitalisation data.2 Exten-
sive heterogeneity in the distributions between differ-
ent states is reported. Quantifying the time-delay for
COVID-19 onset and hospitalisation data provides use-
ful input parameters for many COVID-19 epidemiologi-
cal models, especially those modelling the healthcare re-
sponse in low- and middle-income countries.
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VII. CODE AND DATA AVAILABILITY
Python, R and Stan code used to analyse the data
and fit the distribution is available at https://github.
com/mrc-ide/Brazil_COVID19_distributions, along
with estimated parameters for each state and probability
distribution functions considered at https://github.
com/mrc-ide/Brazil_COVID19_distributions/blob/
master/results/results_full_table.csv. The
SIVEP-Gripe database,2 is available to download
from Brazil Ministry of Health website https://
opendatasus.saude.gov.br/dataset/bd-srag-2020.
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IX. APPENDIX
A. Model selection
To characterise which model (gamma, log-normal, etc.)
best fits the data, the Bayesian model evidence z =
z(y|Mi) is evaluated. Here and throughout this section
y denotes the data and Mi denotes the i
th model from
the analysed model set. As determining the model ev-
idence requires an integral over the model parameters
(θ) which is generally intractable, we approximate it
with z0 = z0(y|Mi), which is based on a second-order
Laplace approximation,35 q0 = q0(Mi, θ|y), to the true
un-normalised posterior density q = q(Mi, θ|y). The
second-order approximated density is estimated as:
q0 = q(θˆ) exp
(
−1
2
(θ − θˆ) Σ−1 (θ − θˆ)T
)
. (5)
Here q(θˆ) denotes the value of the un-normalised poste-
rior evaluated using the mean estimates of the model’s
parameters θˆ, and Σ the covariance matrix built from
MCMC samples of the posterior. From this expression,
a second-order approximation to the model evidence, z0,
is given by z0 = q(θˆ)
√
det(2piΣ−1), where det(·) denotes
the determinant of the matrix.
For each model pair, Bayes factors were computed from
the marginal likelihoods. Considering two models Mi and
Mj , the Bayes Factor (BF) is
Bij =
z(y|Mi)
z(y|Mj) , (6)
where z(y|Mi) is the evidence of model Mi given y. If
Bij > 1, the evidence is in favour of model Mi. Here, for
readability we will report the Bayes Factors as 2 log(Bij)
following Kass and Raftery notation.36
The sensitivity of our model evidence is tested with
respect to the choice of hyperprior distribution, and sec-
ondly with respect to the use of the approximate second-
order density q0. In the latter instance this is done by
performing thermodynamic integration21–23 between q0
and the true density q in order to obtain an asymptoti-
cally exact estimate of the marginal model evidence,
z = z0 exp
(∫ 1
0
Eθ∼q(θ;λ) [log q − log q0] dλ
)
. (7)
The right hand term corrects the z0 approximation to
the exact Bayesian evidence by a path integral evaluated
with respect to a sampling distribution that interpolates
between the two densities as q(θ; λ) = q(1−λ)qλ0 in terms
of the auxiliary coordinate λ.
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Table IV. Probability distribution functions (PDFs) with analytical formulae for mean and variance. y denotes the data, Γ(·)
is a gamma function. GG – generalised gamma, GLN – generalised log-normal.
PDF Mean Variance
Gamma(y|α, β) = βα
Γ(α)
yα−1 exp(−βy) α
β
α
β2
Weibull(y|α, σ) = α
σ
(
y
σ
)α−1
exp
(− ( y
σ
)α)
σΓ
(
1 + 1
α
)
σ2
(
Γ
(
1 + 2
α
)− Γ2 (1 + 1
α
))
Log-normal(y|µ, σ) = 1√
2piσ
1
y
exp
(
− 1
2
(
log y−µ
σ
)2)
exp
(
µ+ σ
2
2
) (
exp
(
σ2
)− 1) exp (2µ+ σ2)
GG(y|a, d, p) = 1
Γ
(
d
p
) ( p
a
)d
xd−1 exp
(− ( y
a
)p)
aΓ((d+1)/p)
Γ(d/p)
a2
[
Γ((d+2)/p)
Γ(d/p)
−
(
Γ((d+2)/p)
Γ(d/p)
)2]
GLN(y|µ, σ, s) = 1
y
s
2
s+1
s σΓ( 1s )
exp
(− 1
2
| log y−µ
σ
|s) exp(µ)
[
1 + 1
2Γ(1/s)
· S
]
S =
∑∞
j=1 σ
j
(
1 + (−1)j
)
2j/s
Γ( j+12 )
Γ(j+1)
exp(2µ)
[
1 + 1
2Γ(1/s)
· S
]
-[Mean]2
S =
∑∞
j=1 2σ
j
(
1 + (−1)j
)
2j/s
Γ( j+12 )
Γ(j+1)
Table V. Bayes Factors (BFs) for the analysed distributions and models. For each dataset (rows), the values represent BF
for the best fitting model against other models. Value of 0 indicates the model that fits the best. Value > 10 indicates a very
strong evidence against given model compared to the best one. GLN - generalised log-normal, GG - generalised gamma. NA -
not analysed. The BF values are reported here as 2 log(Bij) following Kass and Raftery notation.
36
Gamma Weibull Log-normal GLN GG
Onset-to-death 0 2156 2208 198 301
Admission-death 0 195 4349 3096 188
ICU stay 0 231 588 607 352
Onset-to-diagnosis (non-PCR) 578 793 4340 0 461
Onset-to-diagnosis (PCR) 1111 10400 13882 0 1257
Onset-to-hospital-admission 4000 17073 494 0 NA
Onset-to-hospital-discharge 2819 8346 6079 0 3087
Onset-to-ICU-admission 798 4359 142 0 1244
Table VI. State-level onset-to-death estimates for gamma PDF: mean, variance, parameters values, with 95% confidence inter-
vals. Mean and variance given in days. The parameters p1 and p2 are given in the form Gamma(x|p1, p2) = Gamma(α, β).
The full PDFs for other distributions are available at https://github.com/mrc-ide/Brazil_COVID19_distributions/blob/
master/results/results_full_table.csv.
State Mean Variance p1 p2
AC 17.4 (16.1, 18.8) 119.4 (98.8, 143.6) 2.6 (2.2, 2.9) 0.1 (0.1, 0.2)
AL 14.0 (13.4, 14.5) 82.5 (74.3, 91.9) 2.4 (2.2, 2.5) 0.2 (0.2, 0.2)
AM 15.6 (15.3, 16.0) 95.3 (89.1, 102.1) 2.6 (2.4, 2.7) 0.2 (0.2, 0.2)
AP 14.5 (13.2, 16.0) 99.1 (79.8, 122.7) 2.1 (1.9, 2.4) 0.1 (0.1, 0.2)
BA 15.1 (14.7, 15.6) 116.6 (107.9, 126.1) 2.0 (1.9, 2.1) 0.1 (0.1, 0.1)
CE 16.1 (15.8, 16.4) 116.4 (111.1, 122.0) 2.2 (2.2, 2.3) 0.1 (0.1, 0.1)
DF 16.4 (15.6, 17.2) 105.0 (92.7, 119.0) 2.6 (2.3, 2.8) 0.2 (0.1, 0.2)
ES 17.0 (16.4, 17.5) 107.8 (98.2, 118.1) 2.7 (2.5, 2.9) 0.2 (0.1, 0.2)
GO 14.5 (13.8, 15.2) 87.9 (77.9, 99.1) 2.4 (2.2, 2.6) 0.2 (0.2, 0.2)
MA 15.0 (14.6, 15.4) 89.4 (82.7, 96.5) 2.5 (2.4, 2.7) 0.2 (0.2, 0.2)
MG 15.1 (14.6, 15.7) 95.1 (86.3, 104.7) 2.4 (2.2, 2.6) 0.2 (0.1, 0.2)
MS 14.8 (13.3, 16.4) 93.9 (74.8, 116.8) 2.4 (2.0, 2.7) 0.2 (0.1, 0.2)
MT 14.1 (13.1, 15.1) 80.6 (67.2, 96.4) 2.5 (2.2, 2.8) 0.2 (0.2, 0.2)
PA 14.7 (14.5, 15.0) 90.2 (85.7, 94.9) 2.4 (2.3, 2.5) 0.2 (0.2, 0.2)
PB 14.0 (13.4, 14.5) 78.7 (71.2, 87.3) 2.5 (2.3, 2.7) 0.2 (0.2, 0.2)
PE 13.0 (12.7, 13.2) 89.7 (84.6, 95.1) 1.9 (1.8, 1.9) 0.1 (0.1, 0.2)
PI 16.5 (15.6, 17.4) 114.8 (99.4, 131.7) 2.4 (2.1, 2.6) 0.1 (0.1, 0.2)
PR 15.7 (15.1, 16.4) 91.9 (81.8, 102.7) 2.7 (2.5, 2.9) 0.2 (0.2, 0.2)
RJ 14.2 (14.0, 14.4) 103.3 (99.5, 107.3) 2.0 (1.9, 2.0) 0.1 (0.1, 0.1)
RN 15.2 (14.6, 15.9) 91.9 (81.8, 103.0) 2.5 (2.3, 2.7) 0.2 (0.2, 0.2)
RO 14.7 (13.6, 15.8) 92.1 (76.4, 110.0) 2.3 (2.1, 2.6) 0.2 (0.1, 0.2)
RR 11.2 (10.2, 12.1) 68.1 (55.9, 83.0) 1.8 (1.6, 2.1) 0.2 (0.1, 0.2)
RS 15.4 (14.7, 16.2) 116.0 (103.0, 130.8) 2.1 (1.9, 2.2) 0.1 (0.1, 0.1)
SC 17.8 (16.7, 19.0) 146.8 (125.1, 173.5) 2.2 (1.9, 2.4) 0.1 (0.1, 0.1)
SE 13.4 (12.2, 14.5) 112.5 (91.4, 138.6) 1.6 (1.4, 1.8) 0.1 (0.1, 0.1)
SP 16.2 (16.0, 16.4) 114.8 (111.6, 118.0) 2.3 (2.2, 2.3) 0.1 (0.1, 0.1)
TO 14.8 (13.5, 16.2) 97.3 (79.1, 119.7) 2.3 (2.0, 2.6) 0.2 (0.1, 0.2)
Brazil 15.2 (15.1, 15.3) 105.3 (103.7, 106.9) 2.2 (2.2, 2.2) 0.1 (0.1, 0.1)
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Figure 4. Distribution of onset-to-death for Maranho, Rio de Janeiro, So Paulo and Rio Grande do Sul. Anomalous spikes for
the first day can be observed for Maranho and Rio de Janeiro, indicating they might be a reporting error.
Table VII. Pearson correlation coefficients for mean distribution times and socioeconomic indicators.
ICU-stay Onset-death Admission-death Onset-discharge
Onset-hospital
admission
Onset-ICU
admission
Onset-diagnosis
(PCR)
Education -0.32 -0.25 -0.62 0.41 0.48 0.39 0.34
Poverty -0.31 -0.31 -0.68 0.52 0.69 0.54 0.49
Deprivation 0.38 0.35 0.71 -0.49 -0.59 -0.49 -0.41
Wealth -0.08 0.26 0.37 -0.24 -0.07 -0.21 -0.17
Income 0.21 0.28 0.60 -0.35 -0.40 -0.33 -0.35
Segregation 0.40 0.35 0.62 -0.43 -0.57 -0.47 -0.30
Mean age 0.13 0.25 0.43 -0.45 -0.57 -0.68 -0.25
Urbanicity 0.12 0.11 0.43 -0.34 -0.52 -0.40 -0.19
Table VIII. Pearson correlation coefficients for mean distribution times.
Onset-death Admission-death Onset-discharge
Onset-hospital
admission
Onset-ICU
admission
Onset-diagnosis
(PCR)
Onset-death 1 0.69 -0.35 0.06 0.24 0.15
Admission-death 0.69 1 -0.52 -0.48 -0.20 -0.36
Onset-discharge -0.35 -0.52 1 0.39 0.43 0.40
Onset-to-hospital-admission 0.06 -0.48 0.39 1 0.72 0.53
Onset-to-ICU-admission 0.24 -0.20 0.43 0.72 1 0.50
Onset-to-diagnosis (PCR) 0.15 -0.36 0.40 0.53 0.50 1
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Figure 5. Posterior distribution of mean times for onset-to-death, hospital-admission-to-death, onset-to-ICU-admission and
ICU stay, sorted by mean value. Plots are colour-coded by the geographical region which the state belongs to: North (yellow),
Northeast (green), Central-West (orange), Southeast (purple), South (blue).
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Figure 6. Posterior distribution of mean times for onset-to-hospital-admission, onset-to-hospital-discharge, onset-to-diagnosis
(PCR) and onset-to diagnosis (non-PCR), sorted by mean value. Plots are colour-coded by the geographical region which the
state belongs to: North (yellow), Northeast (green), Central-West (orange), Southeast (purple), South (blue).
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Figure 7. Gamma PDF Gamma(α, β) fitted to the onset-to-death data for Brazil and five states of Brazil. The PDFs were fitted
with HMC partially pooling each state with the whole country. The red lines represent the model using the mean parameter
estimates. Individual PDFs selected during MCMC sampling are shown in yellow. Posterior mean and variance distributions
for each region are given in the middle and right hand side columns.
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Figure 8. Estimated mean per distribution in different sce-
narios: excluding 1st day data points (top) and censoring cor-
recting (bottom). The credible intervals were not shown as
due to the large amount of data available they were negligible.
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Table IX. Number of datapoints per state for each of the datasets analysed in the study. Acre (AC), Amazonas (AM), Amap
(AP), Par (PA), Rondnia (RO), Roraima (RR), Tocantins (TO), Alagoas (AL), Bahia (BA), Cear (CE), Maranho (MA),
Paraba (PB), Piau (PI), Pernambuco (PE), Sergipe (SE), Rio Grande do Norte (RN), Distrito Federal (DF), Gois (GO), Mato
Grosso do Sul (MS), Mato Grosso (MT), Esprito Santo (ES), Minas Gerais (MG), Rio de Janeiro (RJ), So Paulo (SP), Paran
(PR), Rio Grande do Sul (RS), Santa Catarina (SC).
ICU-stay Onset-death
Onset-diagnosis
(non-PCR)
Onset-hospital
admission
Onset-Discharge
Onset-ICU
admission
Admission-Death
Onset-diagnosis
(PCR)
AC 2 239 1 225 4 9 115 345
AL 680 1040 416 1600 629 859 894 1344
AM 1010 2736 1604 5971 2573 1323 2403 4502
AP 68 181 153 299 136 80 175 183
BA 982 2241 352 4563 1338 2300 2013 5266
CE 1534 5801 1749 9685 4536 2768 4905 8286
DF 499 662 311 2687 1415 1198 655 2864
ES 589 1292 321 1409 507 778 1023 1774
GO 375 698 122 1813 783 819 637 2018
MA 197 1950 821 1485 247 341 1097 1562
MG 603 1223 604 4782 2210 1521 1176 4910
MS 46 131 126 723 417 171 124 764
MT 83 286 2175 1347 2191 384 248 4695
PA 1270 4727 1351 8226 3034 1993 3934 6921
PB 349 1136 644 1992 508 740 1037 1584
PE 311 4408 190 6574 1888 1566 3284 9745
PI 139 515 240 2161 341 490 497 2314
PR 898 793 124 3174 1952 1168 773 3490
RJ 1490 9750 1446 18019 7438 7165 9068 21159
RN 337 876 544 1878 664 693 821 1517
RO 180 254 293 554 180 284 238 488
RR 53 270 92 98 51 56 265 200
RS 971 790 477 3565 2328 1277 770 4144
SC 291 408 343 1600 777 599 389 1634
SE 193 303 117 938 181 306 295 1116
SP 8515 16348 4769 55735 32937 17642 15808 63184
TO 44 213 53 515 213 87 177 549
